GlassScriptPhysician profile
Lawrence Wayne Liu
NPI 1255890380
$3,649.68
in general payments reported to CMS, 2019-2025
20 companies · $895 in 2025
The $895 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $833 · 2023: $1,147 · 2024: $774 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $644.73 | 2022-2024 | |
| Kite Pharma, INC. | $382.62 | 2024-2025 | Yescarta |
| Janssen Biotech, INC. | $357.22 | 2025 | Talvey, Darzalex, Carvykti |
| Genzyme Corporation | $276.25 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $270.65 | 2022-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $269.11 | 2022-2025 | Enhertu, Calquence |
| Pfizer INC. | $227.11 | 2023-2024 | |
| Beigene USA, INC. | $196.53 | 2023 | Brukinsa |
| Exelixis INC. | $175.00 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $172.09 | 2023-2025 | |
| Seagen INC. | $151.34 | 2023 | Adcetris |
| Gilead Sciences, INC. | $122.11 | 2022 | |
| Sobi, INC | $122.11 | 2022 | |
| Janssen Scientific Affairs, LLC | $109.17 | 2025 | Talvey, Tecvayli, Darzalex |
| Genentech USA, INC. | $68.00 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $25.41 | 2023 | Epkinly, Imbruvica |
| Astellas Pharma US INC | $24.14 | 2023 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $23.88 | 2022 | |
| Daiichi Sankyo INC. | $16.14 | 2025 | Vanflyta |
| Amgen INC. | $16.07 | 2023 | Kyprolis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.